Lenalidomide Genthon

Active Ingredient:: Lenalidomide
Origin:: EU

Lenalidomide Genthon (Lenalidomide)

Q: What is Lenalidomide Genthon used for?

Lenalidomide Genthon contains the active ingredient lenalidomide, an immunomodulatory drug indicated for the treatment of adult patients with multiple myeloma and myelodysplastic syndromes, including those with del(5q) cytogenetic abnormality. It may also be used in combination regimens for certain lymphomas.

Q: How does lenalidomide work?

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, causing degradation of transcription factors Ikaros and Aiolos. This results in enhanced immune cell activity, inhibition of angiogenesis, and direct anti‑myeloma effects, collectively suppressing malignant cell growth.

Q: What is the usual dose of lenalidomide?

The prescribed dose of lenalidomide is individualized by the treating physician based on the specific indication, disease stage, renal function, and patient tolerance. Dosage adjustments are made according to clinical response and laboratory monitoring.

Q: Is lenalidomide safe in pregnancy or breastfeeding?

Lenalidomide is classified as Pregnancy Category X; it is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while on therapy.

Q: How do I order Lenalidomide Genthon from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does lenalidomide compare with its main alternative, thalidomide?

Both lenalidomide and thalidomide belong to the immunomodulatory drug class, but lenalidomide generally offers greater potency, a more favorable safety profile, and reduced risk of peripheral neuropathy. Clinical trials have shown higher response rates in multiple myeloma for lenalidomide, while thalidomide remains an option when lenalidomide is unavailable or contraindicated.

Q: What are the storage and handling requirements for Lenalidomide Genthon?

Lenalidomide tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or bottle to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Q: How is Lenalidomide Genthon administered?

The medication is taken orally, usually once daily on a scheduled cycle (e.g., 21 days on treatment followed by 7 days off), as directed by the prescriber. It should be swallowed whole with water and may be taken with or without food, unless otherwise instructed.

Q: What are the most serious risks associated with lenalidomide therapy?

The most critical risks include severe neutropenia and thrombocytopenia, which can lead to infections or bleeding, and venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism. Patients should be monitored closely for signs of infection, bleeding, or clot formation, and appropriate preventive measures should be implemented.

Q: Who should not use Lenalidomide Genthon?

Lenalidomide is contraindicated in pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled active infections. Caution is also advised for those with severe renal impairment unless dose adjustments are made.

Lenalidomide, the active ingredient in Lenalidomide Genthon, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is employed in the treatment of certain blood cancers, notably multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH India supplies Lenalidomide Genthon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Manufacturer / TM Owner

Genthon Bv

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Lenalidomide is used in hematologic malignancies that respond to immunomodulatory therapy.

Multiple myeloma: improves progression‑free survival and overall response rates in relapsed or refractory disease.
Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission.
Mantle cell lymphoma (in combination with rituximab): enhances overall response when added to standard chemo‑immunotherapy.

How It Works

Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, altering substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which modulates cytokine production, enhances T‑cell and natural killer cell activity, and inhibits angiogenesis. The combined immunomodulatory, anti‑angiogenic, and direct anti‑myeloma actions underlie its antineoplastic effect.

Side Effects

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

Fatigue: persistent tiredness reported by many patients.
Neutropenia: reduced neutrophil count increasing infection risk.
Thrombocytopenia: lowered platelet levels leading to easy bruising.
Diarrhea: loose stools of mild to moderate intensity.
Constipation: difficulty passing stool.
Rash: mild skin eruptions.

Serious or Rare Side Effects

Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism.
Severe neutropenia: profound drop in neutrophils requiring medical intervention.
Severe thrombocytopenia: platelet counts <20 × 10⁹/L with bleeding risk.
Secondary primary malignancies: emergence of new cancers.
Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome.

Precautions & Warnings

When prescribing Lenalidomide, clinicians should observe several safety precautions to minimize risk.

Monitor blood counts: perform complete blood count regularly to detect cytopenias.
Assess thrombotic risk: evaluate history of clotting disorders before initiating therapy.
Avoid pregnancy: contraindicated in pregnancy; ensure effective contraception for both sexes.
Use contraception: employ two reliable methods throughout treatment and for at least four weeks after discontinuation.
Adjust for renal impairment: dose may need modification in patients with reduced kidney function.
Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Avoid Interactions

Lenalidomide interacts with several drug classes; awareness of these interactions guides safe co‑administration.

Major Interactions (Avoid)

Potent CYP3A4 inhibitors (e.g., ketoconazole): can markedly increase lenalidomide exposure.
Potent CYP3A4 inducers (e.g., rifampin): may substantially lower drug levels and reduce efficacy.
Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

Anticoagulants (warfarin): monitor INR closely as bleeding risk may rise.
Antiplatelet agents (aspirin, clopidogrel): watch for additive bleeding tendencies.
Other immunomodulatory agents (e.g., pomalidomide): increased potential for myelosuppression.
CYP3A4 substrates with narrow therapeutic index: consider dose adjustments or therapeutic drug monitoring.

Frequently Asked Questions

Lenalidomide Genthon contains the active ingredient lenalidomide, an immunomodulatory drug indicated for the treatment of adult patients with multiple myeloma and myelodysplastic syndromes, including those with del(5q) cytogenetic abnormality. It may also be used in combination regimens for certain lymphomas.

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, causing degradation of transcription factors Ikaros and Aiolos. This results in enhanced immune cell activity, inhibition of angiogenesis, and direct anti‑myeloma effects, collectively suppressing malignant cell growth.

The prescribed dose of lenalidomide is individualized by the treating physician based on the specific indication, disease stage, renal function, and patient tolerance. Dosage adjustments are made according to clinical response and laboratory monitoring.

Lenalidomide is classified as Pregnancy Category X; it is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory drug class, but lenalidomide generally offers greater potency, a more favorable safety profile, and reduced risk of peripheral neuropathy. Clinical trials have shown higher response rates in multiple myeloma for lenalidomide, while thalidomide remains an option when lenalidomide is unavailable or contraindicated.

Lenalidomide tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or bottle to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

The medication is taken orally, usually once daily on a scheduled cycle (e.g., 21 days on treatment followed by 7 days off), as directed by the prescriber. It should be swallowed whole with water and may be taken with or without food, unless otherwise instructed.

The most critical risks include severe neutropenia and thrombocytopenia, which can lead to infections or bleeding, and venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism. Patients should be monitored closely for signs of infection, bleeding, or clot formation, and appropriate preventive measures should be implemented.

Lenalidomide is contraindicated in pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled active infections. Caution is also advised for those with severe renal impairment unless dose adjustments are made.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 25 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.